All times are listed in CET (Central European Time)
Found 1 Presentation For Request "123P"
123P - Impact of the STK11 mutation on the response to immunotherapy
- A. Kalantari (Woluwe-Saint-Lambert, Belgium)
- A. Kalantari (Woluwe-Saint-Lambert, Belgium)
- T. Pieters (Woluwe-Saint-Lambert, Belgium)
- K. Sawadogo (Woluwe-Saint-Lambert, Belgium)
Abstract
Background
STK11mutation is present in 20% of bronchial adenocarcinoma and is associated with the KRAS mutation in 30% and KEAP1 in 25% of cases. STK11 mutation appears to confer resistance to anti-PD-(L)1. We wanted to analyze the impact of this STK11 mutation on clinical charactericitcs, overall survival (OS) and progression-free survival (PFS) in patients treated with an anti-PD-(L)1 in 1st or 2nd line.
Methods
We conducted a single-center retrospective study of patients with stage IV non-small cell lung cancer treated at Cliniques Universitaires Saint-Luc between September 2017 and June 2020. We isolated 3 groups: STK11mut/KRASmut, STK11mut/KRASwt, STK11wt/KRASmut. The clinical characteristics sought were age at diagnosis, sex, smoking status, histology, stage at diagnosis, status KRAS, STK11, type of treatment in 1st line and second line, PFS and OS.
Results
227 patients with NSCLC had NGS. A total of 95 patients had an STK11 mutation, or KRAS, or both. Of these 95 patients, 44 were included in our study. KRASmut and STK11mut was present respectively in 40.91% and 20.45% of our population while the KRAS/STK11 co-mutation in 38.64%. PD-L1 expression was predominantly present in STK11mut patients (n = 26; >1% in 61.54%; >50% in 23.1%). 34 patients were treated with an anti-PD-(L1), 26 in first line including 11 in combination with chemotherapy and 8 in second line. Taking into account the mutation status and after treatment with immunotherapy, the shortest OS was observed in the STK11mut/KRASmut population with an OS of 6.9 months, compared to 8.3 months in the STK11mut population and 33.9 months in the KRASmut population (CI95: 7.9–33.9/p = 0.018). These results are only significant between the KRASmut and KRASmut/STK11mut groups (p = 0.017). PFS was not statistically different between groups.
Conclusions
This study corroborates the negative impact on OS of STK11 mutation whether or not associated with a KRAS mutation in patients treated with an anti-PD- (L) 1, despite the high level of PD-L1 expression in our population. We could not assess whether STK11 mutation plays a prognostic or a predictive role.
Legal entity responsible for the study
Cliniques Universitaires Saint Luc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.